ReviewTrends in endocrinology and metabolism: TEM2021
Insulin resistance in cardiovascular disease, uremia, and peritoneal dialysis.
Review in Trends in endocrinology and metabolism: TEM, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 56 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
56 citing papers in PubMed, 2 syntheses or guidelines pooled it, 84 citations in OpenAlex.
- Association of triglyceride-glucose index and its related parameters with the risk of stroke: a meta-analysis.BMC neurology · 2025Pooled it
- Mortality of Peritoneal Dialysis versus Hemodialysis in Older Adults: An Updated Systematic Review and Meta-Analysis.Gerontology · 2024Pooled it
- Article
- Explainable machine learning integrating bioelectrical impedance for 6-month cardiovascular risk in peritoneal dialysis.Renal failure · 2026Article
- The impact of serum myokine profile on the outcome of peritoneal dialysis patients.BMC nephrology · 2026Article
- Association of vascular aging and insulin resistance with cardiovascular outcomes in China: PURE cohort study.International journal of surgery (London, England) · 2026Article
- Troxerutin is a novel osmotic agent for peritoneal dialysis with protective cardiovascular actions.Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association · 2026Article
- Association Between Impaired Fasting Glucose and Adverse Outcomes in Patients Treated With Peritoneal Dialysis: A Retrospective Study From Southern China.Endocrinology, diabetes & metabolism · 2026Observational
- Prognostic value of the triglyceride-glucose index in patients with acute ischemic stroke undergoing endovascular treatment.The Journal of international medical research · 2026Article
- Article
- A Novel Peritoneal Dialysis Fluid Based on Succinylated Gelatin and Citrate: A Preliminary Investigation of Efficacy, Safety, and Biocompatibility.Pharmaceuticals (Basel, Switzerland) · 2026Article
- Clinical rationale behind glucose-sparing strategies in peritoneal dialysis: a narrative review.BMC nephrology · 2026Review
- Insulin Resistance Across Cerebrovascular and Related Disorders: Mechanisms, Measurement, Genetics, and Clinical Implications.Neuropsychiatric disease and treatment · 2026Review
- Joint effects of diabetes and time-weighted average multidimensional nutritional indices on mortality in patients undergoing peritoneal dialysis: a landmark analysis.Frontiers in nutrition · 2026Article
- Prognostic significance of the C-reactive protein-triglyceride-glucose index for all-cause and cardiovascular mortality in peritoneal dialysis: a multicenter cohort study.Scientific reports · 2025Article
- Article
- Innovations in peritoneal dialysis fluid: biocompatible formulations and expanded therapeutic applications.Renal failure · 2025Review
- The association between insulin resistance assessed by estimated glucose disposal rate and stroke prevalence and mortality in non-diabetic people: evidence from two prospective cohorts.Diabetology & metabolic syndrome · 2025Article
- Risk factors for cardiovascular death in urgent-start peritoneal dialysis patients: a multicenter retrospective cohort study.Scientific reports · 2025Article
- Effects of different peritoneal dialysis solutions on serum lipid levels and lipid profile in end-stage chronic kidney disease patients undergoing peritoneal dialysis.BMC nephrology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 5 institutions in 4 countries.
Funding
Abstract
Diabetic nephropathy is highly correlated with the occurrence of other complications of type 1 diabetes (T1D) and type 2 diabetes (T2D) mellitus; for example, hypertension with cardiovascular disease (CVD) being the most frequent cause of death in patients with end-stage renal disease and undergoing renal dialysis. Hyperglycemia and insulin resistance (IR) are responsible for the micro- and macrovascular complications of diabetes through different mechanisms. In particular, IR plays a key role in the etiology of atherosclerosis in both diabetic and non-diabetic patients. IR - exacerbated by organ-level selectivity - is more important than glycemic control per se in determining cardiovascular outcomes. This may be exacerbated by the fact that IR is organ and pathway specific due to the only selective loss of sensitivity to insulin action of specific pathways/processes. Therefore, it is counterintuitive that the use of peritoneal dialysis (PD) in (frequently) diabetic renal disease patients should involve their exposure to high daily doses of glucose peritoneally. In view of the controversy about the causal association between glucose load and CVD in PD patients, we discuss the role that selective IR may play in the progression of CVD in diabetic renal end-stage patients. In discussing these associations, we propose that reducing glucose exposure in PD solutions may be beneficial especially if coupled with strategies that address IR directly, and the avoidance of excessive use of insulin treatment in T2D.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.